Maxime Dely: What if We Could Leukoreduce Without a Filter?
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared on LinkedIn:
”What if we could leukoreduce without a filter?
When we talk about leukoreduction, we immediately think of leukocyte filters — disposable devices able to remove over 99% of white blood cells.
But… not everyone has access to them.
In some countries, the cost of this technology remains a major barrier to transfusion safety.
Yet there’s a simple, effective, and affordable alternative: the hard spin.
In many developing countries, the first step in whole blood processing is a soft spin.
This yields two main components:
- a PRP (platelet-rich plasma),
- and an RCC (red cell concentrate).
The issue? Around 90% of the residual white blood cells end up in the RCC.
And these cells can cause febrile non-haemolytic transfusion reactions, allergic reactions, and can even impair red cell storage quality.
By performing a hard spin, we create an interface between plasma and red cells — the well-known buffy coat.
That’s where most white cells accumulate.
The result?
A significant reduction in the residual leukocytes within the red cell concentrate — sometimes divided by 2, from 90% to 50% or even lower, depending on the separation and centrifugation settings.
The hard spin isn’t a miracle solution, but it’s a crucial first step toward safer transfusion, especially where resources are limited.
Because sometimes, innovation simply means doing better with what we have.”
Stay updated with Hemostasis Today.
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders
-
Dec 18, 2025, 16:50Marie Cambot on Innovhem’s Quantification of The HbF/HbS Ratio for SCD
-
Dec 18, 2025, 16:26Yogesh Rathod on Hematological Issues and ICU
-
Dec 18, 2025, 16:09Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
-
Dec 18, 2025, 15:23Michael Hadley: Well-Timed ACC Statement Just Out in JACC Journals
-
Dec 18, 2025, 15:12Wolfgang Miesbach on Insights from Guy Young’s ASH2025 Session on Next-Generation Gene Therapy
-
Dec 18, 2025, 14:15Plasma-Derived Therapy for Hemophilia in The Updated European Medicines Agency’s Union List
-
Dec 18, 2025, 13:55Laurent Bertoletti: BAT-VTE is One of 7 Projects Funded Under the EFFECT Trial Call!
-
Dec 18, 2025, 13:34Alexandru Stieber Explores VEXAS Syndrome
